Factor Xa inhibitors - the XaBans

It’s just another “me too” drug trying to shoehorn its way into the massive warfarin-replacement market - Ryan Radecki

Factor Xa inhibitors - the XaBans

image by: Julie Dalcourt
     

HWN Recommends

The New Anticoagulants

The “xabans” are newly available oral agents; both rivaroxaban and apixaban have been approved by the FDA since 2010. Because their onset of action is rapid (peaks in 2-4 hours), parenteral bridging is often unnecessary. While anticoagulant effect is predictable and monitoring of anticoagulation is not required, a special assay is available if it becomes necessary to monitor the activity of the agent.

Rivaroxaban is approved for surgical DVT prophylaxis, stroke prevention in nonvalvular atrial fibrillation and treatment of DVT and PE. To date, apixaban is only approved for stroke prevention in valvular atrial fibrillation.

read full article

Resources

Related Articles

Stay Connected

©2022 | HealthWorldNet, Inc. | 116628

Last Updated : Thursday, March 31, 2022